TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02778737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-based intervention
Description: Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-based intervention
Description: Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts.
Study: NCT04077216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Description: This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
Study: NCT00855881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Description: tegafur-uracil 1 cap, bid for 1 year
Study: NCT01736995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Tx/Cognitive Behavioral Tx

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Study: NCT02500797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03511937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage Health Warning Label
Description: Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.

Intervention type: OTHER
Group type: OTHER
Intervention: Neutral Label
Description: Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
Study: NCT04042948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
Study: NCT01249079

Intervention type: OTHER
Intervention: No intervention would be provided in this research
Description: No intervention would be provided in this research,but need to draw blood
Study: NCT04378543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ART352-L
Description: recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
Study: NCT00357006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 100 mcg adjunctive transdermal estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 200 mcg adjunctive transdermal estradiol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: adjunctive transdermal placebo
Study: NCT03171961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online visit group
Description: subjects has online visit with dietitian every 2 weeks+diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic visit group
Description: Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-directed group
Description: self-directed group receives nutritional information via web and their energy needs for weight loss
Study: NCT00981448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc acetate
Description: 50mg of elemental zinc to be administered 2 times daily orally for 14 days.
Study: NCT01216189

Intervention type: RADIATION
Intervention: Preoperative radiotherapy
Description: Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
Study: NCT03370978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment.
Study: NCT03651570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTSD Coach
Description: PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Game application
Description: This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
Study: NCT00513916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: High or low dose of soy isoflavones in the diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy isoflavones
Description: High or low dose of soy isoflavones in the diet.
Study: NCT04623632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominus plane block
Description: transversus abdominus plane block using 40 ml of bupivacaine 0.25%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominus plane placebo
Description: injection of 40 ml of normal saline in the transversus abdominus plane
Study: NCT03352037

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET scan
Description: Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
Study: NCT03636893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT Chemotherapy
Description: 5-FU+Leucovorin+Docetaxel+Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX Chemotherapy
Description: Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
Study: NCT03983811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy
Description: Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
Study: NCT01301027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill a day for 26 weeks
Study: NCT00541385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate
Description: The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemeter lumefantrine
Description: The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to \<15 = 1 tablet, 15 to \<25 kg = 2 tablets), for 3 consecutive days.
Study: NCT04072900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide
Description: 4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Description: 3mg/kg, ivgtt, Q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: 3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Topical Cream
Description: topical application on the injection site 6 hours before each NeoAntigen peptides injection
Study: NCT02572908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sourdough wheat bread

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular yeast baked toast bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains

Intervention type: OTHER
Group type: OTHER
Intervention: Gluten-free diet
Description: Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten-free diet
Description: Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
Study: NCT03265314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LeadHer
Description: The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sassy Science
Description: The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
Study: NCT05533736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis
Description: Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.
Study: NCT02144896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle splinting
Description: Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
Study: NCT02353975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
Study: NCT03715348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate (PCC)
Description: PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma a blood component manufactured from whole blood collection.
Study: NCT02765750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraoperative positive messages
Description: The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraoperative positive messages
Description: The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No message
Description: The headphones will be placed on patient's ears but no message will be played.
Study: NCT03387618

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital PET/CT imaging
Description: Next generation PET/CT imaging
Study: NCT04411667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam
Description: Standard of Care plus Octagam infusion for 3 days.
Study: NCT04355169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT00135551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blockers
Description: benidipine+angiotensin receptor blocker, titlation scheme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β-blockers
Description: benidipine+β-blockers, titlation scheme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazide diuretics
Description: benidipie+thiazide diuretics, titlation scheme
Study: NCT00679900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: 5 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lormetazepam
Description: 1 mg/day
Study: NCT04205877

Intervention type: DEVICE
Intervention: Transcatheter PDA Closure
Description: Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
Study: NCT02064023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump
Description: subjects in the experimental arm will administer insulin using a pump

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multiple daily insulin injection
Description: Subjects will continue with usual insulin injections
Study: NCT03807206

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Patient questionnaire
Study: NCT01840982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed grain 1
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed grain 2
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White rice
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.
Study: NCT00690781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse casein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spread casein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse milk soluble protein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spread milk soluble protein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
Study: NCT02056587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
Study: NCT03780166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily at the cohort-specified dose level.
Study: NCT03537521

Intervention type: PROCEDURE
Intervention: Urgent surgery which can not be postponed to the next 24 hrs
Description: The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.

Intervention type: PROCEDURE
Intervention: Urgent surgery which can not be postponed to the next 24 hrs
Description: The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
Study: NCT04593537

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention is involved

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention is involved
Study: NCT04677088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T cells
Description: Patients will receive 1 x 10\^4 cells/kg to 5 x 10\^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
Study: NCT04379895

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Pulsed or heated RF ablation of the genicular nerves will be done as an Acceptable treatment for OA of the knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Pulsed or heated RF ablation of the genicular nerves will be done as an Acceptable treatment for OA of the knee
Study: NCT00493129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak (Denileukin Diftitox)
Description: 9 µg/kg by vein Days 1-5 of a 21 day cycle.
Study: NCT00544297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 gel
Description: Two day application, 0.05%